Business Context and Reporting Period
This Form 8-K Current Report, dated July 29, 2022, details material definitive agreements entered into by TherapeuticsMD, Inc. (TXMD). The filing primarily addresses a private placement equity offering and amendments to existing debt financing arrangements to secure working capital.
Key Financial Metrics and Capital Structure
- Capital Raised: The Company received gross proceeds of $15 million from a private placement offering.
- Equity Issuance: The offering consisted of 15,000 shares of newly designated Series A Preferred Stock and 565,000 shares of Common Stock.
- Debt Maturity Extension: The maturity date of the existing Financing Agreement with Sixth Street Specialty Lending, Inc. was extended to September 30, 2022, with options to extend further to October 31, 2022, and November 30, 2022, contingent on raising at least $7 million in additional equity.
- Warrant Issuance: The Company issued warrants to lenders to purchase 185,000 shares of Common Stock at an exercise price of $0.01 per share, expiring November 26, 2022.
Material Changes and Transaction Details
The filing reports the following material changes to the Company's capital structure and agreements:
- Series A Preferred Stock Terms: The stock has a stated value of $1,000 per share and a liquidation preference of $1,333 per share. It matures on December 31, 2022, at which point the Company is required to redeem the shares at the liquidation preference price. Dividends are payable at 25% of cash dividends paid on Common Stock.
- Redemption Rights: Holders may require redemption at the liquidation preference price upon certain change of control transactions or if the Company fails to comply with covenants or commences bankruptcy proceedings.
- Debt Covenants: The Certificate of Designation prohibits the Company from incurring certain indebtedness or liens while the Series A Preferred Stock is outstanding.
- Bylaw Amendment: The Board adopted an amendment to the Bylaws to render Nevada's acquisition of controlling interest statutes inapplicable to the transactions described in this filing.
Outlook, Risks, and Management Commentary
The Company intends to use the net proceeds from the $15 million offering for working capital and general corporate purposes. The extension of the debt maturity is conditional; the Company must raise not less than $7 million in cash proceeds from an equity issuance (on terms substantially similar to the Series A Preferred Stock) to exercise the option to extend the debt maturity beyond September 30, 2022. The filing does not provide specific revenue guidance or operational outlook beyond the immediate liquidity needs addressed by the financing.
Investor Verification Checklist
- Verify the Company's ability to meet the mandatory redemption obligation of approximately $19.995 million (15,000 shares x $1,333) due on December 31, 2022.
- Confirm whether the Company has secured the additional $7 million in equity proceeds required to extend the debt maturity beyond September 30, 2022.
- Review the specific covenants in the Certificate of Designation that restrict future indebtedness and liens.
- Assess the dilution impact of the 565,000 Common Stock shares and 185,000 Lender Warrants issued.
- Examine the Company's current cash position and burn rate to determine if the $15 million proceeds are sufficient to sustain operations until the preferred stock maturity.